FollowMyHealth Patient Portal

Richard Leo Wahl, MD

Elizabeth Mallinckrodt Professor, Radiology
Chairman, Department of Radiology
Director, Mallinckrodt Institute of Radiology

Specialty Areas

Diagnostic Radiology
Nuclear Medicine
Nuclear Radiology

Board Certifications

Nuclear Medicine
Diagnostic Radiology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

PET/CT imaging, radiopharmaceutical therapies, nuclear Imaging

  • Maps & Directions
  • Education
  • Publication & Research
  • Financial Disclosures

Maps & Directions

Maps & Directions

Barnes-Jewish Hospital
Mallinckrodt Institute of Radiology

510 South Kingshighway Boulevard
St. Louis, MO 63110

Office Phone: (314) 362-7100

Education

Education

Medical Degree: Washington University School of Medicine, St. Louis, MO 1978
ScD: Wartburg College, Waverly, IA 2008
Fellowship, Nuclear Medicine: Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 1983
Fellowship (research), Immunology: Howard Hughes Medical Institute, Washington University School of Medicine, St. Louis, MO 1983
BA, Chemistry: Wartburg College, Waverly, IA 1974
Residency, Diagnostic Radiology: Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 1982

Publication & Research

Publication & Research

Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors.
Jacobs MA, Macura KJ, Zaheer A, Antonarakis ES, Stearns V, Wolff AC, Feiweier T, Kamel IR, Wahl RL, Pan L
Acad Radiol. 2018 Apr 4; pii: S1076-6332(18)30095-3. doi: 10.1016/j.acra.2018.02.010.

PMID:
    29627288
    [PubMed - as supplied by publisher]
Related citations


Measurement of Brown Adipose Tissue Activity Using Microwave Radiometry (MRAD) and FDG PET/CT.
Crandall J, O JH, Gajwani P, Leal JP, Mawhinney DD, Sterzer F, Wahl RL
J Nucl Med. 2018 Feb 9; pii: jnumed.117.204339. doi: 10.2967/jnumed.117.204339.

PMID:
    29439011
    [PubMed - as supplied by publisher]
Related citations


Feasibility Evaluation of Myocardial Cannabinoid Type 1 Receptor Imaging in Obesity: A Translational Approach.
Valenta I, Varga ZV, Valentine H, Cinar R, Horti A, Mathews WB, Dannals RF, Steele K, Kunos G, Wahl RL, Pomper MG, Wong DF, Pacher P, Schindler TH
JACC Cardiovasc Imaging. 2018 Feb; 11(2 Pt 2)320-332. doi: 10.1016/j.jcmg.2017.11.019.

PMID:
    29413441
    [PubMed - in process]
Related citations


PERCIST in Perspective.
O JH, Wahl RL
Nucl Med Mol Imaging. 2018 Feb; 52(1)1-4. doi: 10.1007/s13139-017-0507-4.

PMID:
    29391906
    [PubMed]
Related citations


Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with Zirconium 89 in Human Lymphoma Xenografts.
Yoon JT, Longtine MS, Marquez-Nostra BV, Wahl RL
J Nucl Med. 2018 Jan 18; pii: jnumed.117.203299. doi: 10.2967/jnumed.117.203299.

PMID:
    29348316
    [PubMed - as supplied by publisher]
Related citations


Quantitative PET/CT in clinical practice: assessing the agreement of PET tumor indices using different clinical reading platforms.
Mhlanga JC, Chirindel A, Lodge MA, Wahl RL, Subramaniam RM
Nucl Med Commun. 2018 Feb; 39(2)154-160. doi: 10.1097/MNM.0000000000000786.

PMID:
    29227348
    [PubMed - in process]
Related citations


Non-invasive methods for the assessment of brown adipose tissue in humans.
Chondronikola M, Beeman SC, Wahl RL
J Physiol. 2018 Feb 1; 596(3)363-378. doi: 10.1113/JP274255.

PMID:
    29119565
    [PubMed - in process]
Related citations


DNA Repair After Exposure to Ionizing Radiation Is Not Error-Free.
Duncan JR, Lieber MR, Adachi N, Wahl RL
J Nucl Med. 2018 Feb; 59(2)348. doi: 10.2967/jnumed.117.197673.

PMID:
    28775198
    [PubMed - in process]
Related citations


Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.
Holdhoff M, Ye X, Supko JG, Nabors LB, Desai AS, Walbert T, Lesser GJ, Read WL, Lieberman FS, Lodge MA, Leal J, Fisher JD, Desideri S, Grossman SA, Wahl RL, Schiff D
Neuro Oncol. 2017 Jun 1; 19(6)845-852. doi: 10.1093/neuonc/nox020.

PMID:
    28371832
    [PubMed - indexed for MEDLINE]
Related citations


Quantitation of Cancer Treatment Response by <sup>18</sup>F-FDG PET/CT: Multicenter Assessment of Measurement Variability.
O JH, Jacene H, Luber B, Wang H, Huynh MH, Leal JP, Wahl RL
J Nucl Med. 2017 Sep; 58(9)1429-1434. doi: 10.2967/jnumed.117.189605.

PMID:
    28360211
    [PubMed - indexed for MEDLINE]
Related citations


Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point <sup>18</sup>F-FDG PET/CT Imaging in Patients with Advanced Melanoma.
Cho SY, Lipson EJ, Im HJ, Rowe SP, Gonzalez EM, Blackford A, Chirindel A, Pardoll DM, Topalian SL, Wahl RL
J Nucl Med. 2017 Sep; 58(9)1421-1428. doi: 10.2967/jnumed.116.188839.

PMID:
    28360208
    [PubMed - indexed for MEDLINE]
Related citations


The effect of regadenoson on the integrity of the human blood-brain barrier, a pilot study.
Jackson S, George RT, Lodge MA, Piotrowski A, Wahl RL, Gujar SK, Grossman SA
J Neurooncol. 2017 May; 132(3)513-519. doi: 10.1007/s11060-017-2404-1.

PMID:
    28315063
    [PubMed - indexed for MEDLINE]
Related citations


Simplifying volumes-of-interest (VOIs) definition in quantitative SPECT: Beyond manual definition of 3D whole-organ VOIs.
Vicente EM, Lodge MA, Rowe SP, Wahl RL, Frey EC
Med Phys. 2017 May; 44(5)1707-1717. doi: 10.1002/mp.12164.

PMID:
    28207950
    [PubMed - in process]
Related citations


A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-IIIA resectable NSCLC.
Crandall JP, Tahari AK, Juergens RA, Brahmer JR, Rudin CM, Esposito G, Subramaniam DS, Knopp MV, Hall NC, Gajwani P, Leal JP, Lodge MA, O JH, Gabrielson EW, Shankar LK, Wahl RL
EJNMMI Res. 2017 Dec; 7(1)8. doi: 10.1186/s13550-017-0258-3.

PMID:
    28102506
    [PubMed]
Related citations


Spatiotemporal distribution modeling of PET tracer uptake in solid tumors.
Soltani M, Sefidgar M, Bazmara H, Casey ME, Subramaniam RM, Wahl RL, Rahmim A
Ann Nucl Med. 2017 Feb; 31(2)109-124. doi: 10.1007/s12149-016-1141-4.

PMID:
    27921285
    [PubMed - indexed for MEDLINE]
Related citations


Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma.
Jacene H, Crandall J, Kasamon YL, Ambinder RF, Piantadosi S, Serena D, Kasecamp W, Wahl RL
Mol Imaging Biol. 2017 Jun; 19(3)429-436. doi: 10.1007/s11307-016-1019-9.

PMID:
    27798787
    [PubMed - indexed for MEDLINE]
Related citations


Comparison of quantitative Y-90 SPECT and non-time-of-flight PET imaging in post-therapy radioembolization of liver cancer.
Yue J, Mauxion T, Reyes DK, Lodge MA, Hobbs RF, Rong X, Dong Y, Herman JM, Wahl RL, Geschwind JH, Frey EC
Med Phys. 2016 Oct; 43(10)5779.

PMID:
    27782730
    [PubMed - indexed for MEDLINE]
Related citations


Repeatability of <sup>18</sup>F-FLT PET in a Multicenter Study of Patients with High-Grade Glioma.
Lodge MA, Holdhoff M, Leal JP, Bag AK, Nabors LB, Mintz A, Lesser GJ, Mankoff DA, Desai AS, Mountz JM, Lieberman FS, Fisher JD, Desideri S, Ye X, Grossman SA, Schiff D, Wahl RL
J Nucl Med. 2017 Mar; 58(3)393-398. doi: 10.2967/jnumed.116.178434.

PMID:
    27688473
    [PubMed - indexed for MEDLINE]
Related citations


Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival.
Koshkin VS, Bolejack V, Schwartz LH, Wahl RL, Chugh R, Reinke DK, Zhao B, O JH, Patel SR, Schuetze SM, Baker LH
J Clin Oncol. 2016 Aug 29; pii: JCO681858.

PMID:
    27573658
    [PubMed - as supplied by publisher]
Related citations


Brown Adipose Reporting Criteria in Imaging STudies (BARCIST 1.0): Recommendations for Standardized FDG-PET/CT Experiments in Humans.
Chen KY, Cypess AM, Laughlin MR, Haft CR, Hu HH, Bredella MA, Enerbäck S, Kinahan PE, Lichtenbelt Wv, Lin FI, Sunderland JJ, Virtanen KA, Wahl RL
Cell Metab. 2016 Aug 9; 24(2)210-22. doi: 10.1016/j.cmet.2016.07.014.

PMID:
    27508870
    [PubMed - indexed for MEDLINE]
Related citations

Financial Disclosures

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

This physician reported the following financial interests during calendar year 2017:

Company Name: Nihon Mediphysics

Royalties:

Equity: No

Consulting/Advisory Board: $20,000 - $39,999

Speaker Fees:

Reporting Date: May 01, 2018


Company Name: Clarity

Royalties:

Equity: No

Consulting/Advisory Board: $10,000 - $19,999

Speaker Fees:

Reporting Date: May 01, 2018

Areas of Research Interest

Quantitative imaging, radioimmunotherapy, imaging the immune system, multi-modality imaging